TWI666207B - 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 - Google Patents

一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 Download PDF

Info

Publication number: TWI666207B
Authority: TW; Taiwan
Prior art keywords: solvent; solvents; water; cancer; crystal form
Prior art date: 2017-06-20

Application number

TW107121069A

Other languages

English (en)

Chinese (zh)

Other versions

TW201904954A (zh

Inventor

尤凌峰

邵成

馮君

Original Assignee

大陸商江蘇恒瑞醫藥股份有限公司

大陸商上海恒瑞醫藥有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-20

Filing date

2018-06-20

Publication date

2019-07-21

2018-06-20 Application filed by 大陸商江蘇恒瑞醫藥股份有限公司, 大陸商上海恒瑞醫藥有限公司 filed Critical 大陸商江蘇恒瑞醫藥股份有限公司

2019-02-01 Publication of TW201904954A publication Critical patent/TW201904954A/zh

2019-07-21 Application granted granted Critical

2019-07-21 Publication of TWI666207B publication Critical patent/TWI666207B/zh

Links

239000013078 crystal Chemical group 0.000 title claims abstract description 70
150000003839 salts Chemical class 0.000 title claims abstract description 35
238000002360 preparation method Methods 0.000 title claims abstract description 22
LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 67
-1 3-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl Chemical group 0.000 claims abstract description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 7
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
239000002904 solvent Substances 0.000 claims description 99
239000012046 mixed solvent Substances 0.000 claims description 50
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 40
238000006243 chemical reaction Methods 0.000 claims description 36
238000000634 powder X-ray diffraction Methods 0.000 claims description 35
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 29
CQKGUVATZAOISO-XASBMLQQSA-N (E)-3-[4-[(1R,3R)-2-(4-cyclopropylphenyl)-6-(1-ethylpyrazol-4-yl)-3-methyl-3,4-dihydro-1H-isoquinolin-1-yl]phenyl]prop-2-enoic acid Chemical compound CCn1cc(cn1)-c1ccc2[C@H](N([C@H](C)Cc2c1)c1ccc(cc1)C1CC1)c1ccc(\C=C\C(O)=O)cc1 CQKGUVATZAOISO-XASBMLQQSA-N 0.000 claims description 28
238000000034 method Methods 0.000 claims description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 25
230000007547 defect Effects 0.000 claims description 22
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
238000002425 crystallisation Methods 0.000 claims description 18
102000015694 estrogen receptors Human genes 0.000 claims description 18
108010038795 estrogen receptors Proteins 0.000 claims description 18
239000004472 Lysine Substances 0.000 claims description 17
150000002825 nitriles Chemical class 0.000 claims description 17
230000008025 crystallization Effects 0.000 claims description 16
235000019766 L-Lysine Nutrition 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
206010006187 Breast cancer Diseases 0.000 claims description 12
208000026310 Breast neoplasm Diseases 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
150000002576 ketones Chemical class 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
150000008282 halocarbons Chemical class 0.000 claims description 10
239000005456 alcohol based solvent Substances 0.000 claims description 9
150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
201000011510 cancer Diseases 0.000 claims description 8
206010014733 Endometrial cancer Diseases 0.000 claims description 7
206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
206010033128 Ovarian cancer Diseases 0.000 claims description 7
150000001335 aliphatic alkanes Chemical class 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
239000004215 Carbon black (E152) Substances 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
206010060862 Prostate cancer Diseases 0.000 claims description 6
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
230000001419 dependent effect Effects 0.000 claims description 6
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 6
239000004210 ether based solvent Substances 0.000 claims description 6
229930195733 hydrocarbon Natural products 0.000 claims description 6
150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 5
230000001404 mediated effect Effects 0.000 claims description 5
125000004971 nitroalkyl group Chemical group 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
210000000748 cardiovascular system Anatomy 0.000 claims description 4
210000003169 central nervous system Anatomy 0.000 claims description 4
RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 claims description 4
235000018977 lysine Nutrition 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 claims description 3
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
206010008342 Cervix carcinoma Diseases 0.000 claims description 3
208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 3
208000031220 Hemophilia Diseases 0.000 claims description 3
208000009292 Hemophilia A Diseases 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
208000000453 Skin Neoplasms Diseases 0.000 claims description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
150000001409 amidines Chemical class 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 3
239000008280 blood Substances 0.000 claims description 3
210000004369 blood Anatomy 0.000 claims description 3
201000010881 cervical cancer Diseases 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 3
150000002430 hydrocarbons Chemical class 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
230000006698 induction Effects 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
229940011051 isopropyl acetate Drugs 0.000 claims description 3
239000005453 ketone based solvent Substances 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
230000002503 metabolic effect Effects 0.000 claims description 3
230000000926 neurological effect Effects 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000001850 reproductive effect Effects 0.000 claims description 3
201000000849 skin cancer Diseases 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
206010046766 uterine cancer Diseases 0.000 claims description 3
239000008096 xylene Substances 0.000 claims description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
229910002483 Cu Ka Inorganic materials 0.000 claims description 2
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims description 2
NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
239000003759 ester based solvent Substances 0.000 claims description 2
230000003340 mental effect Effects 0.000 claims description 2
LYGJENNIWJXYER-BJUDXGSMSA-N nitromethane Chemical group [11CH3][N+]([O-])=O LYGJENNIWJXYER-BJUDXGSMSA-N 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000005855 radiation Effects 0.000 claims description 2
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 2
230000015572 biosynthetic process Effects 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
238000005516 engineering process Methods 0.000 abstract description 2
239000000243 solution Substances 0.000 description 31
239000000047 product Substances 0.000 description 25
239000007787 solid Substances 0.000 description 20
238000012360 testing method Methods 0.000 description 17
238000001228 spectrum Methods 0.000 description 16
238000005160 1H NMR spectroscopy Methods 0.000 description 11
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
238000003756 stirring Methods 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 7
238000000113 differential scanning calorimetry Methods 0.000 description 7
239000003480 eluent Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000000825 pharmaceutical preparation Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000000262 estrogen Substances 0.000 description 6
239000012065 filter cake Substances 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
239000012074 organic phase Substances 0.000 description 6
229940095743 selective estrogen receptor modulator Drugs 0.000 description 6
239000000333 selective estrogen receptor modulator Substances 0.000 description 6
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
102000007594 Estrogen Receptor alpha Human genes 0.000 description 5
229940119564 Selective estrogen receptor downregulator Drugs 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
230000007774 longterm Effects 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229960002258 fulvestrant Drugs 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002274 desiccant Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
229960001603 tamoxifen Drugs 0.000 description 3
OBSLWIKITOYASJ-YDEIVXIUSA-N (3r,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical class CN[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-YDEIVXIUSA-N 0.000 description 2
ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000011259 mixed solution Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000010926 purge Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
HCVOPFJFJCPIPT-UHFFFAOYSA-N 1-(3-hydroxyphenyl)propan-2-one Chemical compound CC(=O)CC1=CC=CC(O)=C1 HCVOPFJFJCPIPT-UHFFFAOYSA-N 0.000 description 1
UCRIXEWTILHNCG-UHFFFAOYSA-N 1-ethyl-2h-pyridine Chemical compound CCN1CC=CC=C1 UCRIXEWTILHNCG-UHFFFAOYSA-N 0.000 description 1
BAQHNTRPTIDCSH-UHFFFAOYSA-N 2-(4-cyclopropylphenyl)-3-methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-6-ol Chemical compound C1(CC1)C1=CC=C(C=C1)N1C(C2=CC=C(C=C2CC1C)O)C1=CC=CC=C1 BAQHNTRPTIDCSH-UHFFFAOYSA-N 0.000 description 1
KNEACWHGVGAXFL-UHFFFAOYSA-N 2-aminoethanolate Chemical compound NCC[O-] KNEACWHGVGAXFL-UHFFFAOYSA-N 0.000 description 1
125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
REPDQSDYBMKFPT-UHFFFAOYSA-N 3-[2-(4-cyclopropylanilino)propyl]phenol Chemical compound C1(CC1)C1=CC=C(C=C1)NC(CC=1C=C(C=CC=1)O)C REPDQSDYBMKFPT-UHFFFAOYSA-N 0.000 description 1
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
RNBSVMVXEJNTQZ-UHFFFAOYSA-N 4-cyclopropylaniline;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1C1CC1 RNBSVMVXEJNTQZ-UHFFFAOYSA-N 0.000 description 1
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical group COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
102100038595 Estrogen receptor Human genes 0.000 description 1
101710196141 Estrogen receptor Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000007824 aliphatic compounds Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000012296 anti-solvent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
150000008365 aromatic ketones Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
150000001717 carbocyclic compounds Chemical class 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000002483 hydrogen compounds Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000009304 pastoral farming Methods 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229940125944 selective estrogen receptor degrader Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000002411 thermogravimetry Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW107121069A 2017-06-20 2018-06-20 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 TWI666207B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
??201710466845.3		2017-06-20
CN201710466845		2017-06-20

Publications (2)

Publication Number	Publication Date
TW201904954A TW201904954A (zh)	2019-02-01
TWI666207B true TWI666207B (zh)	2019-07-21

Family

ID=64737482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW107121069A TWI666207B (zh)	2017-06-20	2018-06-20	一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法

Country Status (3)

Country	Link
CN (1)	CN110536888B (fr)
TW (1)	TWI666207B (fr)
WO (1)	WO2018233591A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2022156737A1 (fr) *	2021-01-22	2022-07-28	四川海思科制药有限公司	Forme cristalline d'un composé anti-virus de la grippe, procédé de préparation de la forme cristalline et utilisation de la forme cristalline
WO2023221978A1 (fr) *	2022-05-17	2023-11-23	北京诺康达医药科技股份有限公司	Sel de polylysine, son procédé de préparation et son procédé de purification
CN119707916A (zh) *	2024-12-17	2025-03-28	广东工业大学	基于蛋白-药物相互作用的关键氨基酸诱导曲格列汀新晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015092634A1 (fr) *	2013-12-16	2015-06-25	Novartis Ag	Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TN2015000516A1 (en) *	2013-05-28	2017-04-06	Astrazeneca Ab	Chemical compounds
US9708305B2 (en) *	2013-08-21	2017-07-18	UNIVERSITé LAVAL	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases
KR20180095564A (ko) *	2015-12-22	2018-08-27	지앙수 헨그루이 메디슨 컴퍼니 리미티드	벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도

2018
- 2018-06-19 CN CN201880026325.3A patent/CN110536888B/zh active Active
- 2018-06-19 WO PCT/CN2018/091781 patent/WO2018233591A1/fr not_active Ceased
- 2018-06-20 TW TW107121069A patent/TWI666207B/zh not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015092634A1 (fr) *	2013-12-16	2015-06-25	Novartis Ag	Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes

Also Published As

Publication number	Publication date
WO2018233591A1 (fr)	2018-12-27
TW201904954A (zh)	2019-02-01
CN110536888A (zh)	2019-12-03
CN110536888B (zh)	2022-07-26

Publication	Publication Date	Title
CN103501777B (zh)	2015-08-19	N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的药学上可接受的共晶和其制备方法
EP3248983B1 (fr)	2020-04-01	Forme cristalline a de l'acide obéticholique et son procédé de préparation
TWI772424B (zh)	2022-08-01	一種苯并呋喃類衍生物游離鹼的晶型及製備方法
JP2018520205A (ja)	2018-07-26	レンバチニブメシル酸塩の新規結晶形及びその製造方法
WO2018188643A1 (fr)	2018-10-18	Sel agoniste du récepteur opioïde (mor), forme cristalline du sel de fumarate i correspondante et procédé de préparation de celui-ci
TWI666207B (zh)	2019-07-21	一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法
WO2018117267A1 (fr)	2018-06-28	Sel de composé pipéridine substitué
JP6816036B2 (ja)	2021-01-20	ヒストン脱アセチル化阻害剤の結晶形態
JP2022553833A (ja)	2022-12-26	エストロゲン受容体調節薬の塩及び形態
CN108884099B (zh)	2021-10-08	一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN108778280B (zh)	2021-07-27	一种GnRH受体拮抗剂的多晶型及其制备方法
TWI745764B (zh)	2021-11-11	一種鴉片類物質受體激動劑的結晶形式及製備方法
TW201827436A (zh)	2018-08-01	一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN113840605B (zh)	2024-05-28	N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
TWI717859B (zh)	2021-02-01	一種鴉片類物質受體激動劑的結晶形式及製備方法
CN111349076B (zh)	2022-07-26	一种苯并哌啶类衍生物的l-赖氨酸盐的晶型及其制备方法
RU2761213C2 (ru)	2021-12-06	Соль и полиморф фенил-пиримидонового соединения, их фармацевтическая композиция и применение
TW201713628A (zh)	2017-04-16	一種雄性激素受體抑制劑的結晶形式及其製備方法
CN108026043A (zh)	2018-05-11	一种萘环化合物的晶型
US20230106142A1 (en)	2023-04-06	Crystals of alkynyl-containing compound, salt and solvate thereof, preparation method, and applications
TW202333694A (zh)	2023-09-01	稠環衍生物的晶型、其製備方法及其應用
WO2024109727A1 (fr)	2024-05-30	Forme cristalline d'un sel pharmaceutiquement acceptable d'un dérivé de pyrazolo hétéroaryle
HK40009119A (en)	2020-06-19	Crystal of benzofuran derivative free base and preparation method
HK40009119B (en)	2021-03-05	Crystal of benzofuran derivative free base and preparation method
WO2019029477A1 (fr)	2019-02-14	Forme cristalline de diméalate d'inhibiteur de tyrosine kinase et son procédé de préparation

Legal Events

Date	Code	Title	Description
2023-04-21	MM4A	Annulment or lapse of patent due to non-payment of fees